[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016; 66, 115−32. doi:  10.3322/caac.21338
[2] Song J, Zou SR, Guo CY, et al. Prevalence of thyroid nodules and its relationship with iodine status in Shanghai: a population-based study. Biomed Environ Sci, 2016; 29, 398−407.
[3] Liu ZT, Lin AH. Dietary factors and thyroid cancer risk: a meta-analysis of observational studies. Nutr Cancer, 2014; 66, 1165−78. doi:  10.1080/01635581.2014.951734
[4] Kim HJ, Park HK, Byun DW, et al. Iodine intake as a risk factor for BRAF, mutations in papillary thyroid cancer patients from an iodine-replete area. Eur J Nutr, 2017; 57, 1−7.
[5] Zhao H, Li H, Huang T. High urinary iodine, thyroid autoantibodies, and thyroid-stimulating hormone for papillary thyroid cancer risk. Biol Trace Element Research, 2018; 184, 317−24. doi:  10.1007/s12011-017-1209-6
[6] WHO Assessment of iodine deficiency disorders and monitoring their elimination: a guide for programme managers, 3rd Edition. WHO, Switzerland. 2007.
[7] Jin X, Jiang P, Liu L, et al. The application of serum iodine in assessing individual iodine status. Clin Endocrinol (Oxf), 2017; 87, 807−14. doi:  10.1111/cen.13421
[8] Lee JH, Song RY, Yi JW, et al. Case-control study of papillary thyroid carcinoma on urinary and dietary iodine status in south korea. World J Surg, 2018; 42, 1424−31. doi:  10.1007/s00268-017-4287-x
[9] Haymart MR, Glinberg SL, Liu J, et al. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf), 2009; 71, 434−9. doi:  10.1111/j.1365-2265.2008.03489.x
[10] Lu L, Wu G, Cai R, et al. Clinical study of the relationship between thyroid nodules and calcification and thyroid cancer. Chin J General Surg 4, 2011; 4, 286-8. (In Chinese)
[11] Nagano J, Mabuchi K, Yoshimoto Y, et al. Case-control study in hiroshima and nagasaki examining non-radiation risk factors for thyroid cancer. J Epidemiol, 2007; 17, 76−85. doi:  10.2188/jea.17.76
[12] Katja KV, Mingzhao X. Association of cigarette smoking with aberrant methylation of the tumor suppressor gene rarβ2 in papillary thyroid cancer. Frontiers in Endocrinology, 2011; 2, 99.
[13] Negro R, Valcavi R, Toulis KA. Incidental thyroid cancer in toxic and non-toxic goiter: is TSH associated with malignancy rate? results of a meta-analysis. Endocrine Pract, 2013; 19, 212−8. doi:  10.4158/EP12234.OR
[14] Fighera TM, Perez CL, Faris N, et al. TSH levels are associated with increased risk of thyroid carcinoma in patients with nodular disease. Endokrynol Pol, 2015; 66, 480−5. doi:  10.5603/EP.a2015.0059
[15] Lee EK, Chung KW, Min HS, et al. Preoperative serum thyroglobulin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules. J Korean Med Sci, 2012; 27, 1014−8. doi:  10.3346/jkms.2012.27.9.1014
[16] Guan H, Li C, Li Y, et al. High iodine intake is a risk factor of post-partum thyroiditis: result of a survey from Shenyang, China. J Endocrinol Invest, 2005; 28, 876−81. doi:  10.1007/BF03345318
[17] Choi SY, Park H, Kang MK, et al. The relationship between the BRAF V600E, mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol, 2013; 11, 1−5. doi:  10.1186/1477-7819-11-1